Geron Corporation announced that Aleksandra Rizo, M.D., Ph.D., notified Geron Corporation of her decision to resign from her position as Executive Vice President and Chief Medical Officer of the Company, with her last day of employment being July 8, 2022. Dr. Rizo resigned in order to accept a leadership position with a privately-held discovery and preclinical-stage platform biotechnology company; not because of her assessment of any clinical data related to the ongoing Phase 3 clinical trials or any disagreement relating to the Company's management, board of directors, operations, financial statements, internal controls, policies or practices. Accordingly, Dr. Rizo will continue as a consultant to the Company as Senior Medical and Regulatory Advisor to the Company's development and regulatory teams and will assist in the assessment of data for top-line results from the ongoing IMerge Phase 3 trial in lower risk myelodysplastic syndromes and, assuming supportive top-line results, through the planned FDA New Drug Application submission and acceptance process for imetelstat in lower risk MDS.

Effective as of July 9, 2022, Faye Feller, M.D., will assume the duties and responsibilities of Executive Vice President and Chief Medical Officer of the Company. Dr. Feller, age 40, joined Geron in 2019 as Vice President, Clinical Development and has provided hematology-oncology medical expertise to the clinical science and operations teams in the execution and monitoring of clinical trials. In addition, she has served as the primary medical point of contact between Geron and other medically qualified healthcare professionals, including clinical investigators, prescribers, medical professionals at payer organizations and regulatory authorities.

Prior to Geron, Dr. Feller was Senior Director at Janssen Research and Development, LLC and both a Compound Lead and Study Responsible Physician for multiple clinical trials of early and late-stage development assets at Janssen, including the IMbark Phase 2 clinical trial of imetelstat where she was responsible for protocol writing, regulatory interactions, medical monitoring, study results interpretation and preparation of abstracts and final study reports. Prior to Janssen, Dr. Feller was an attending physician and instructor in the leukemia department of Memorial Sloan Kettering Cancer Center in New York. Dr. Feller holds a B.A. from New York University and an M.D. from Mount Sinai School of Medicine.

She completed her residency in internal medicine at Mount Sinai Hospital and her fellowship in medical oncology at Memorial Sloan Kettering Cancer Center.